ASC

Quantum Announces Timing for the Reporting of Financial Results and other Business Matters

Retrieved on: 
onsdag, maj 29, 2024

Jamie Lerner, Chairman and CEO, and Kenneth Gianella, Chief Financial Officer, will host a conference call on the same day.

Key Points: 
  • Jamie Lerner, Chairman and CEO, and Kenneth Gianella, Chief Financial Officer, will host a conference call on the same day.
  • The timing of the filing and conference call is in conjunction with the Company’s conclusion of its review of previously announced accounting matters.
  • Also today, Quantum announced a revised agreement with its lenders to amend the Company’s existing term loan and revolving credit agreements.
  • These amendments, among other things, waived the total net leverage ratio financial covenant for the quarter ended March 31, 2024.

AtlasClear Holdings, Inc. Announces First Quarter 2024 Financial Results

Retrieved on: 
tisdag, maj 28, 2024

AtlasClear Holdings, Inc. (“AtlasClear Holdings” or “AtlasClear”) (NYSE American: ATCH) announced that their financial results for the first quarter ended March 31, 2024, have been released.

Key Points: 
  • AtlasClear Holdings, Inc. (“AtlasClear Holdings” or “AtlasClear”) (NYSE American: ATCH) announced that their financial results for the first quarter ended March 31, 2024, have been released.
  • See footnote 9 to the financial statements included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, for additional information.
  • As such the operation results consolidated during the three months period ended March 31, 2024, only include the operation of Wilson-Davis from February 9, 2024, through March 31, 2024.
  • AtlasClear will discuss its first quarter financial results during a teleconference today, at 8:30 a.m. (ET).

‘Play well, win well’: new Australian sports chair Kate Jenkins faces challenges and opportunities

Retrieved on: 
tisdag, maj 28, 2024

The Australian Sport Commission (ASC) has appointed Kate Jenkins as its new board chair, replacing Josephine Sukkar, who was the first female chair appointed to the ASC board in 2021.

Key Points: 
  • The Australian Sport Commission (ASC) has appointed Kate Jenkins as its new board chair, replacing Josephine Sukkar, who was the first female chair appointed to the ASC board in 2021.
  • Jenkins was an ambassador for the 2020 T20 Women’s World Cup and the 2023 FIFA Women’s World Cup and participated in the Australian Human Rights Commission’s Independent Review of Gymnastics Australia in 2021.

What is Jenkins’ vision with the ASC?

  • It was responsible for more than A$222 million in sport-related grants last financial year.
  • Jenkins’ vision is for sport “to be safe, fair, accessible and inclusive for everyone.
  • “Play Well” focuses on participation in sport by all Australians and safe, fair and inclusive opportunities for all Australians participating in sport.

What else must Jenkins and the ASC prioritise?

  • The new chair of the ASC must find a way to boost women’s sport participation, develop elite female sport pathways and ensure sustainability in women’s sport at the highest level.
  • Australia now has seven professional women’s sport leagues and young girls can now see future opportunities in elite sport – not just in soccer but in traditionally male-dominated sports.
  • Jenkins, previously an Australian sex discrimination commissioner, should also be well placed to fight the discrimination and harassment prevalent in women’s sport.
  • Cultural change is needed within sport clubs if younger generations of females want to participate more regularly in these sports.

A brighter future?

LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results

Retrieved on: 
fredag, maj 24, 2024

SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended March 31, 2024.

Key Points: 
  • SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended March 31, 2024.
  • First Quarter 2024 Financial Results:
    Operating revenue increased by 8.7% from RMB2,983 million in the first quarter of 2023 to RMB3,242 million in the first quarter of 2024.
    Credit facilitation service income increased by 25.2% from RMB2,116 million in the first quarter of 2023 to RMB2,648 million in the first quarter of 2024.
  • Income tax expense is RMB53.4 million in the first quarter of 2024, as compared to RMB74.3 million in the first quarter of 2023.
  • Net income decreased by 38.4% from RMB327 million in the first quarter of 2023 to RMB202 million in the first quarter of 2024.

Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024

Retrieved on: 
torsdag, maj 16, 2024

ROSELAND, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and announces financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The U.S. E-commerce revenue for the three months ended March 31, 2024 was approximately $1.3 million compared to $989,000 at March 31, 2023.
  • For the three months ended March 31, 2024, international revenue was approximately $930,000, a decrease of $274,000, compared to March 31, 2023.
  • Gross profit for the first quarter ended March 31, 2024, was $1.7 million or 75% of revenue versus $1.9 million or 73% of revenue for the first quarter ended March 31, 2023.
  • Operating loss for the three months ended March 31, 2024, was approximately $(1.5) million versus approximately $(1.3) million for the first quarter ended March 31, 2023.

Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
tisdag, maj 14, 2024

HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights.

Key Points: 
  • HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the quarter ended March 31, 2024 and provided business highlights.
  • The Company closed its merger with a wholly owned subsidiary of AgeX Therapeutics, Inc.
  • The combined company began trading on the NYSE American market under the ticker symbol “SER” on March 27, 2024.
  • On March 26, 2024, the Company’s secured, convertible line of credit from Juvenescence Limited was increased by $2,400,000, which was drawn entirely on March 29, 2024.

Firsthand Technology Value Fund Announces First Quarter Financial Results, NAV of $0.02 Per Share

Retrieved on: 
tisdag, maj 14, 2024

During the quarter, shares of Revasum, Inc. (ASX: RVS) were suspended from trading on the Australian Securities Exchange (ASX).

Key Points: 
  • During the quarter, shares of Revasum, Inc. (ASX: RVS) were suspended from trading on the Australian Securities Exchange (ASX).
  • Effective March 31, 2024, the Fund has entered into a fee waiver agreement with its investment adviser, Firsthand Capital Management, Inc. (“FCM”).
  • For the quarter ended March 31, 2024, the Fund reported total investment income of approximately $32 thousand.
  • The Fund reported net realized and unrealized losses on investments of approximately $3.9 million for the quarter.

The Container Store Group, Inc. Announces Fourth Quarter and Full Fiscal Year 2023 Financial Results

Retrieved on: 
tisdag, maj 14, 2024

For the fourth quarter of fiscal 2023:

Key Points: 
  • For the fourth quarter of fiscal 2023:
    Consolidated net sales were $206.0 million, down 20.7%, compared to the fourth quarter of fiscal 2022.
  • Consolidated depreciation and amortization increased 14.5% to $11.9 million in the fourth quarter of fiscal 2023 from $10.4 million in the fourth quarter of fiscal 2022.
  • The effective tax rate was 25.3% in the fourth quarter of fiscal 2023, as compared to negative 1.7% in the fourth quarter of fiscal 2022.
  • Adjusted EBITDA* was $15.4 million in the fourth quarter of fiscal 2023 compared to $29.2 million in the fourth quarter of fiscal 2022.

Two Constitution Surgery Alliance Facilities are Named in U.S. News & World Report's Inaugural "Best Ambulatory Surgery Centers" Edition

Retrieved on: 
tisdag, maj 14, 2024

AVON, Conn., May 14, 2024 /PRNewswire/ -- East Bay Surgery Center ("East Bay") and Middlesex Endoscopy Center ("Middlesex") have been recognized by U.S. News & World Report among the 2024-2025 Best Ambulatory Surgery Centers.

Key Points: 
  • AVON, Conn., May 14, 2024 /PRNewswire/ -- East Bay Surgery Center ("East Bay") and Middlesex Endoscopy Center ("Middlesex") have been recognized by U.S. News & World Report among the 2024-2025 Best Ambulatory Surgery Centers.
  • Both East Bay and Middlesex are operated and jointly owned by Constitution Surgery Alliance ("CSA"), a leading national developer and operator of ambulatory surgery centers (ASCs).
  • East Bay, an AAAHC-accredited facility in Swansea, Massachusetts, was named in the Best Ophthalmology category.
  • U.S. News awards the designation of "Best Ambulatory Surgery Centers" only to those surgical centers that satisfy U.S. News' statistical assessment of performance.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
tisdag, maj 14, 2024

Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.